社区门诊项目中美罗培南持续输注的血浆浓度:病例系列
该病例系列报告了4例通过门诊肠外抗菌治疗(OPAT)项目接受美罗培南持续输注的患者,所有患者均达到至少2倍最低抑菌浓度(MIC)的血药浓度,感染并发症缓解,未观察到不良反应。作者认为由于患者间药代动力学变异,持续输注美罗培南期间应强制进行血药浓度监测。
要点
- 4例患者经OPAT持续输注美罗培南均达≥2倍MIC血药浓度。
- 所有患者感染并发症缓解,未观察到美罗培南持续输注不良反应。
- 因患者间药代动力学变异,持续输注美罗培南期间应强制监测血药浓度。
核心结论
- 美罗培南持续输注联合治疗药物监测可在社区项目中成功使用。
- 由于患者间药代动力学变异,持续输注美罗培南期间应强制进行血药浓度监测。
研究设计与样本
- 单中心4例患者的病例系列,患者通过门诊肠外抗菌治疗(OPAT)项目接受美罗培南持续输注。
主要发现
- 所有患者在接受美罗培南持续输注期间达到至少2倍MIC的血药浓度。
- 所有患者感染并发症缓解,未观察到美罗培南持续输注的不良反应。
临床怎么用
- 在社区OPAT项目中可考虑美罗培南持续输注,并应强制进行血药浓度监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Traditionally meropenem has been considered too unstable in solution for continuous infusion. However, in the era of increasing antimicrobial resistance, use of meropenem is becoming more frequently required, and the ability to facilitate its administration via community-based programs would be beneficial. There are some reassuring data about meropenem stability in solution, but data about actual drug exposure in patients and subsequent clinical outcomes are lacking. SUMMARY: Here we present a case series of 4 patients at a single tertiary center who received meropenem via continuous infusion coordinated through an outpatient parenteral antimicrobial treatment (OPAT) program. We provide plasma drug concentrations achieved and report on the patients' clinical progress. All patients achieved drug concentrations of at least 2 times the minimum inhibitory concentration (MIC) while receiving meropenem via continuous infusion and had resolution of their infectious complications. No adverse effects of meropenem continuous infusion were noted. CONCLUSION: Meropenem continuous infusion along with therapeutic drug monitoring was used successfully in a community-based program. Due to interpatient pharmacokinetic variability, we consider meropenem concentration monitoring compulsory during continuous-infusion meropenem therapy.
引用
- Legg A, Halford M, McCarthy K, et al. Plasma concentrations resulting from continuous infusion of meropenem in a community-based outpatient program: A case series. Am J Health Syst Pharm. 2020. PMID: 33274740. doi:10.1093/ajhp/zxaa319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。